Stay updated on AT2220 Safety Study in Pompe Disease Clinical Trial
Sign up to get notified when there's something new on the AT2220 Safety Study in Pompe Disease Clinical Trial page.

Latest updates to the AT2220 Safety Study in Pompe Disease Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content changes, particularly the removal of detailed descriptions regarding a study on duvoglustat for Pompe disease, including its purpose, methodology, and inclusion/exclusion criteria. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference24%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check87 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check95 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to AT2220 Safety Study in Pompe Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AT2220 Safety Study in Pompe Disease Clinical Trial page.